Headquartered in Lewisville, TX·Fiscal year ends December·NASDAQ: OFIX·orthofix.com
About Orthofix Medical
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company focused on musculoskeletal care. It sells spinal implants, therapeutic solutions (bone growth stimulation, formerly Bone Growth Therapies), limb reconstruction systems, biologics and enabling technologies. The company reports through Global Spine (Therapeutic Solutions plus Spinal Implants, Biologics and Enabling Technologies) and Global Limb Reconstruction segments.
Key products by area:
- Spinal implants: VIRATA, NorthStar OCT, Mariner, WaveForm and Reef.
- Bone growth stimulators: AccelStim, SpinalStim, PhysioStim and CervicalStim, using PEMF technology.
- Biologics: Trinity Elite, OsteoStrand Plus, OsteoCove and OsteoBallast.
- Limb reconstruction: FITBONE, TRUELOK Elevate, TL-HEX and Galaxy Gemini.
- Enabling technologies: the 7D FLASH Navigation System, a radiation-free, machine-vision image-guided spine surgery system, placed through capital purchase, lease or the Voyager earnout program that ties placements to recurring implant and biologics purchases.
The company sells largely through distributor networks, with U.S. Spine accounting for most of spine revenue. It targets an addressable market of roughly $16 billion. It is currently restructuring its U.S. Spine distribution and instrument-set deployment and has discontinued its M6 product lines. It also continues to integrate its prior merger with SeaSpine. Updated
A loss where analysts modeled a profit is the swing that matters for a $318 million market cap. Orthofix cut full-year sales guidance to $825 million to $830 million from $845 million to $855 million after U.S. Spine revenue fell on supplier delays and instrument-set shortages. Resources are shifting to top distributors before the Q4 VIRATA launch.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company focused on musculoskeletal care. It sells spinal implants, therapeutic solutions (bone growth stimulation, formerly Bone Growth Therapies), limb reconstruction systems, biologics and enabling technologies.
What is the OFIX stock price target?
The Wall Street consensus 12-month price target for OFIX is $10.00.